Advertisement

Topics

Latest "Locus Discovery Incorporated" News Stories

17:07 EDT 24th April 2018 | BioPortfolio

Here are the most relevant search results for "Locus Discovery Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Locus Discovery Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Locus Discovery Incorporated for you to read. Along with our medical data and news we also list Locus Discovery Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Locus Discovery Incorporated Companies for you to search.

Showing "Locus Discovery Incorporated" News Articles 1–25 of 3,500+

Tuesday 24th April 2018

Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2018 financial results on Tuesday, May 8, 2018, after the U.S. financial markets close. Five Prime will host a conference call and liv


Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Rα, Into Clinical Development

TAICANG, China, April 24, 2018 /PRNewswire/ -- Connect Biopharmaceuticals, Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic inflammation. The planned phase 1 clinical trial is a randomized, double-blind, placebo-controlled study in healthy subjects to evaluate the ...

The Fuzzy Free-For-All

I wrote here about the way that disordered proteins seem to be able to bind together tightly in the apparent absence of a defined structure, and along the way I expressed a desire not to lead any drug discovery efforts against such systems. Now here’s another example of protein fuzziness, and I can’t say that


Ligand to Report First Quarter 2018 Results on May 8th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2018 financial results on May 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. First Quarter 2018 Earnings Call Wha...

Simulations Plus Announces Employee Bonuses

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees. Walt Woltosz, chairman and chief executive officer of Si...

Concept Life Sciences appoints Matilda Bingham as Site Director and David Higton as Biotransformation and Metabolite Identification Expert, at its Alderley Park site

Appointments support expansion of expertise in integrated drug discovery and development Manchester, UK, 24 April 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformat...

Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2018, after the U.S. markets close on May 8, 2018. Enanta managem...

X-Biotix Therapeutics, Inc. Secures $7 million in Series A Financing

Announces Key Additions to Board of Directors and Senior Management X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multi-drug-resistant (MDR) Gram-negative pathogens, announced that the company has secured $7 million in a Series A financing ...

Gateway for Cancer Research Announces Completion of Phase I Clinical Trial Using “Tumor Paint” in Pediatric Brain Cancer Surgery

Dr. Sarah Leary, pediatric oncologist at Seattle Children’s Hospital, completes trial of Tumor Paint BLZ-100 in 28 children undergoing brain tumor removal surgery Gateway for Cancer Research (Gateway), a non-profit dedicated to funding transformational cancer research, announces the completion of a Phase I clinical project led by Dr. Sarah ...

Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics

Company is targeting upstream aspects of native protein degradation pathways to develop new therapies for cancer Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock...

Drug Discovery Informatics Market to Grow Rapidly Owing to Increasing Usage of Cloud-Based ...

The continuous advancements in software for the endowment of data visualization, data processing and analysis and data aggregation for the adoption of more automated and Read more...

Redx impresses with appointment of AstraZeneca veteran as new CEO

(WebFG News) - AIM-quoted drug discovery and development firm Redx has found its new chief executive officer in former AstraZeneca UK president Lisa Anson, marking a "new beginning" as the company ...

REVOLUTION Medicines Raises $56 Million Series B Financing

-- Company also expands executive team and board of directors with industry leaders -- REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities. The financing wa...

Spotlight On Israel: Compugen Comes Forth

Compugen, a predictive drug discovery and development company, plays an important role within Israel's biopharma sector as one of the...   

LDC opens branch in Munich

The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies. LDC Biologics will produce, optimise and ...

Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Peripheral Arterial Disease PAD/ Pulmonary Vascular Disease PVD development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equi...

Monday 23rd April 2018

NF-κB1 gene known to drive cancer development is critical for preventing stomach cancers

Melbourne researchers have made the surprise discovery that the 'odd one out' in a family of proteins known to drive cancer development is instead critical for preventing stomach cancers.

Porphyria Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Porphyria Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Porphyria development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indi...

Novel pathway identified in development of acute myeloid leukemia with poor prognosis

(National University of Singapore, Yong Loo Lin School of Medicine) NUS researchers have discovered a new pathway by which a severe form of acute myeloid leukemia (AML) develops. The main player in the pathway, a protein called SHARP1, promotes leukemia development and maintenance, both on its own and through its actions on other genes. The discovery could lead to the development of novel SHARP1-s...

Scientists unearth vital link between fat, immunity and heat regulation

(Trinity College Dublin) Scientists from Trinity College Dublin have discovered a key, previously unknown role for a population of cells that live in our fat -- these cells regulate our body heat and protect us against cold shock. The discovery opens the door to future treatments in which weight loss (or gain) is the desired goal, as activating the pathway involved may stimulate the body to burn (...

How colorectal cancer cells spread to the liver

(Sanford-Burnham Prebys Medical Discovery Institute) A new study by Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers helps explain the connection between a tumor suppressor called protein kinase C zeta (PKC zeta) and metastatic colorectal cancer.

Bacteremia Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

"Bacteremia Pipeline Insight, 2018 report by DelveInsight offers comprehensive Insight of the pipeline under development therapeutics scenario and growth prospects across Bacteremia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated in...

ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be accessed in the...

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform. ...

NantKwest to Present at Upcoming Science & Medicine Conferences

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018. The presentations will feature a review of the company’s R&D efforts, along with a clinical update provided by company managem...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks